PTIX
Protagenic Therapeutics, Inc.NASDAQHealthcare$0.53+0.00%ClosedMarket Cap: $1.0M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.43
P/S
0.00
EV/EBITDA
-0.25
DCF Value
$-1.43
FCF Yield
-403.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
184.9%
ROA
-241.8%
ROIC
379.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-925.1K | $2.2M | $1.14 | — |
| FY 2025 | $0.00 | -Infinity% | $-5.8M | $-5.2M | $-3.45 | — |
| Q3 2025 | $0.00 | -Infinity% | $-1.1M | $-869.5K | $-0.47 | — |
| Q2 2025 | $0.00 | -Infinity% | $-2.3M | $-5.1M | $-1.37 | — |
| Q1 2025 | $0.00 | -Infinity% | $-1.4M | $-1.4M | $-2.75 | — |
| Q4 2024 | $-25.1K | 200.0% | $-1.6M | $-1.6M | $-0.24 | — |
| FY 2024 | $0.00 | -Infinity% | $-5.7M | $-5.5M | $-1.13 | — |
| Q3 2024 | $0.00 | -Infinity% | $-652.0K | $-641.0K | $-0.14 | — |
| Q2 2024 | $0.00 | -Infinity% | $-1.7M | $-1.6M | $-0.36 | — |
| Q1 2024 | $0.00 | -Infinity% | $-1.7M | $-1.7M | $-5.44 | — |
| Q4 2023 | $0.00 | -Infinity% | $-1.2M | $-1.7M | $-0.38 | — |
| FY 2023 | $0.00 | -Infinity% | $-4.5M | $-5.0M | $-1.15 | — |